MX2025008735A - Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion - Google Patents

Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion

Info

Publication number
MX2025008735A
MX2025008735A MX2025008735A MX2025008735A MX2025008735A MX 2025008735 A MX2025008735 A MX 2025008735A MX 2025008735 A MX2025008735 A MX 2025008735A MX 2025008735 A MX2025008735 A MX 2025008735A MX 2025008735 A MX2025008735 A MX 2025008735A
Authority
MX
Mexico
Prior art keywords
composition
same
preparing
pharmaceutical formulation
formulation including
Prior art date
Application number
MX2025008735A
Other languages
English (en)
Spanish (es)
Inventor
Aeri Kim
Jungmin Yun
John Kim
Original Assignee
Onconic Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc, Jeil Pharmaceutical Co Ltd filed Critical Onconic Therapeutics Inc
Publication of MX2025008735A publication Critical patent/MX2025008735A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2025008735A 2023-02-01 2025-07-25 Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion MX2025008735A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230013947 2023-02-01
PCT/IB2024/050869 WO2024161316A1 (en) 2023-02-01 2024-01-31 Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition

Publications (1)

Publication Number Publication Date
MX2025008735A true MX2025008735A (es) 2025-11-03

Family

ID=92024104

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025008735A MX2025008735A (es) 2023-02-01 2025-07-25 Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion

Country Status (15)

Country Link
EP (1) EP4658244A1 (https=)
JP (1) JP2026505092A (https=)
KR (1) KR20240121186A (https=)
CN (1) CN118415999A (https=)
AR (1) AR131668A1 (https=)
AU (1) AU2024215883A1 (https=)
CL (1) CL2025002270A1 (https=)
CO (1) CO2025011347A2 (https=)
DO (1) DOP2025000185A (https=)
IL (1) IL322431A (https=)
JO (1) JOP20250189A1 (https=)
MX (1) MX2025008735A (https=)
PE (1) PE20252396A1 (https=)
TW (1) TW202432120A (https=)
WO (1) WO2024161316A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120827558A (zh) * 2024-04-19 2025-10-24 丽珠医药集团股份有限公司 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682133A1 (en) * 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
AR051041A1 (es) * 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
FI20086158A0 (fi) * 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
KR101777971B1 (ko) * 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
AR131668A1 (es) 2025-04-16
CO2025011347A2 (es) 2025-09-18
IL322431A (en) 2025-09-01
KR20240121186A (ko) 2024-08-08
AU2024215883A1 (en) 2025-07-31
JP2026505092A (ja) 2026-02-10
CN118415999A (zh) 2024-08-02
DOP2025000185A (es) 2026-02-15
EP4658244A1 (en) 2025-12-10
CL2025002270A1 (es) 2025-10-03
TW202432120A (zh) 2024-08-16
JOP20250189A1 (ar) 2025-07-28
PE20252396A1 (es) 2025-10-10
WO2024161316A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
MX2025008735A (es) Composicion inyectable, formulacion farmaceutica que incluye la misma y metodo para preparar la composicion
IL116566A0 (en) Imidazo (4 5-c)quinolin amines and pharmaceutical compositions containing them
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2002070438A3 (en) Compositions for delivering bisphosphonates
MX2023002792A (es) Preparacion farmaceutica.
MY143795A (en) Tetrahydropyridoindole derivatives
SI2041133T1 (sl) Imidazo (1,2,a)piridin-2-karboksamidni derivati, njihova priprava in njihova uporaba v terapevtiki
MX2011009190A (es) Sales derivadas de tetrahidro-imidazo[1,5-a]piracina, metodos de preparacion y uso medicinal de las mismas.
WO2021009676A8 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonists
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2018038988A3 (en) Imidazo[1,2-a]pyridin compounds, compositions comprising them, methods for treating diseases using them, and methods for preparing them
MX2025000988A (es) Nueva sal del compuesto de imidazo[1,2-a]piridina, forma cristalina de la misma y metodo de preparacion
EP4617276A3 (en) Pyruvate kinase r (pkr) activating compositions
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
EP4516318A3 (en) 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
MY129437A (en) Drug formulation having controlled release of active compound
MX2025005209A (es) Compuestos lipídicos y usos de los mismos
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
UA95223C2 (ru) Производные пиридопиримидина, их получение, их применение в терапии
MX2021000683A (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de trk.
GEP20247606B (en) Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
MX2025006411A (es) Formulacion de un inhibidor de pan-jak
MX2025008780A (es) Formulacion farmaceutica, metodo de preparacion para la misma y composicion de tableta
MX2023004565A (es) Fosfato de vitamina d3 y sales farmaceuticamente aceptables de este, composiciones farmaceuticas que comprenden el compuesto y metodos para preparar el compuesto.
PL1699468T3 (pl) Środek farmaceutyczny zawierający kompleks cynk-hialuronian do leczenia stwardnienia rozsianego